Objective: To explore the therapeutic mechanism of Tiaoxin Recipe and Bushen Recipe (BSR, ) in treating Alzheimer’s d isease (AD). Methods: Sixty patients with AD were divided into 3 groups according to their MMSE an...Objective: To explore the therapeutic mechanism of Tiaoxin Recipe and Bushen Recipe (BSR, ) in treating Alzheimer’s d isease (AD). Methods: Sixty patients with AD were divided into 3 groups according to their MMSE and ADL scores before treatment, using randomized block design. They were treated separately with TXR, BSR and Donepezil (Dp) for 12 weeks. The changes of MMSE score, ADL score, neuro-psychology amount table score, including FOM, RVR, DS and BD, as well as the overall operational evaluation before and after treatment were analyzed. Results: The recognition and daily life capacity of patients in the 3 groups were improved after treatment. MMSE score in the TXR group increased from 16.10±1.94 scores before treatment to 17 90±2 59 scores after treatment, in the BSR group, from 16 15±2 16 to 17 50±2 59, and in the Dp group, from 17 35±1 90 to 19 60±3 39, all showed significant difference (all P<0 01). Change of ADL score showed that in the TXR group, it lowere d from 43 10±3 86 to 41 50±4 40, in the BSR group from 43 30±4 53 to 41 60±4 12 and in the Dp group, from 42 95±3 58 to 40 60±5 23, which also showed significan t difference (P<0 05 or P<0 01). Moreover, increase of FOM, RVR and DS score was shown in the TXR and the Dp group, and increase of RVR and BD score was shown in the BSR group, with significant difference in compar ison of corresponding score before and after treatment, inter-groups comparison showed significant difference of FOM score between the BSR and the Dp group ( P<0 01). Overall operational evaluation (total effective rate) in the TXR group was 70%, in the BSR group 65% and in Dp group 75%, with no significant difference among them. Conclusion: TXR and BSR are effective TCM drugs in treating AD展开更多
Objective: To observe the clinical efficacy of Xin'anning Nasal Drop (XAND,心安宁滴鼻剂) in treating coronary heart disease with unstable angina pectoris (CHD-UAP). Methods: Sixty patients with CHD-UAP were ass...Objective: To observe the clinical efficacy of Xin'anning Nasal Drop (XAND,心安宁滴鼻剂) in treating coronary heart disease with unstable angina pectoris (CHD-UAP). Methods: Sixty patients with CHD-UAP were assigned, according to the randomizing number table, to two groups, the control group treated with conventional Western medicine, and the treated group treated with conventional Western medicine plus XAND. The clinical efficacy and the changes of S-T segment in resting EKG and total ischemia burden (TIB) in 24-h dynamic EKG were observed. Results: The clinical efficacy, including the effect of angina alleviation, its initiation, and the effect of TOM syndrome score reduction, were significantly superior in the treated group to those in the control group ( P〈0.05 or P〈0.01 ). The degree and extent of myocardial ischemia were significantly improved in both groups ( P〈0.01 ), but the improvement in the treated group was better than that in the control group ( P〈0.05). Moreover, it was worth mentioning that the immediate effect in the treated group was better than that in the control group, and the reduction of TIB, the improvement in heart rate and myocardial oxygen consumption ( immediately after the first administration or by the end of the therapeutic course), and systolic blood pressure after treatment in the former were all superior to those in the latter, showing significant difference ( P〈0.05 or P〈0.01 ). Conclusion: XAND has a quick effect in alleviating angina in patients with CHD-UAP, and it is worthy of further studies and spreading in clinical practice.展开更多
文摘Objective: To explore the therapeutic mechanism of Tiaoxin Recipe and Bushen Recipe (BSR, ) in treating Alzheimer’s d isease (AD). Methods: Sixty patients with AD were divided into 3 groups according to their MMSE and ADL scores before treatment, using randomized block design. They were treated separately with TXR, BSR and Donepezil (Dp) for 12 weeks. The changes of MMSE score, ADL score, neuro-psychology amount table score, including FOM, RVR, DS and BD, as well as the overall operational evaluation before and after treatment were analyzed. Results: The recognition and daily life capacity of patients in the 3 groups were improved after treatment. MMSE score in the TXR group increased from 16.10±1.94 scores before treatment to 17 90±2 59 scores after treatment, in the BSR group, from 16 15±2 16 to 17 50±2 59, and in the Dp group, from 17 35±1 90 to 19 60±3 39, all showed significant difference (all P<0 01). Change of ADL score showed that in the TXR group, it lowere d from 43 10±3 86 to 41 50±4 40, in the BSR group from 43 30±4 53 to 41 60±4 12 and in the Dp group, from 42 95±3 58 to 40 60±5 23, which also showed significan t difference (P<0 05 or P<0 01). Moreover, increase of FOM, RVR and DS score was shown in the TXR and the Dp group, and increase of RVR and BD score was shown in the BSR group, with significant difference in compar ison of corresponding score before and after treatment, inter-groups comparison showed significant difference of FOM score between the BSR and the Dp group ( P<0 01). Overall operational evaluation (total effective rate) in the TXR group was 70%, in the BSR group 65% and in Dp group 75%, with no significant difference among them. Conclusion: TXR and BSR are effective TCM drugs in treating AD
文摘Objective: To observe the clinical efficacy of Xin'anning Nasal Drop (XAND,心安宁滴鼻剂) in treating coronary heart disease with unstable angina pectoris (CHD-UAP). Methods: Sixty patients with CHD-UAP were assigned, according to the randomizing number table, to two groups, the control group treated with conventional Western medicine, and the treated group treated with conventional Western medicine plus XAND. The clinical efficacy and the changes of S-T segment in resting EKG and total ischemia burden (TIB) in 24-h dynamic EKG were observed. Results: The clinical efficacy, including the effect of angina alleviation, its initiation, and the effect of TOM syndrome score reduction, were significantly superior in the treated group to those in the control group ( P〈0.05 or P〈0.01 ). The degree and extent of myocardial ischemia were significantly improved in both groups ( P〈0.01 ), but the improvement in the treated group was better than that in the control group ( P〈0.05). Moreover, it was worth mentioning that the immediate effect in the treated group was better than that in the control group, and the reduction of TIB, the improvement in heart rate and myocardial oxygen consumption ( immediately after the first administration or by the end of the therapeutic course), and systolic blood pressure after treatment in the former were all superior to those in the latter, showing significant difference ( P〈0.05 or P〈0.01 ). Conclusion: XAND has a quick effect in alleviating angina in patients with CHD-UAP, and it is worthy of further studies and spreading in clinical practice.